Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01254773 · ClinicalTrials.gov registry record · Phase 2
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
NCT01254773: Completed Phase 2 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
NCT01254773 is a Phase 2 study that has completed, run by JANSSEN Alzheimer Immunotherapy Research & Development. The registered enrollment target is 146 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01254773, a Phase 2 study, has completed, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
Study Summary
This study in individuals with mild to moderate Alzheimer's Disease is designed to assess:(1) safety and tolerability (2) the capacity of subcutaneous bapineuzumab to reduce brain amyloid load as measured by positron emission tomography (PET) scans.
Interventions
- DRUG Experimental Bapineuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01254773
The ClinicalTrials.gov registry entry for NCT01254773 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Experimental Bapineuzumab is the first listed.
NCT01254773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01254773 about?
NCT01254773 is a clinical study titled "Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease". This study in individuals with mild to moderate Alzheimer's Disease is designed to assess:(1) safety and tolerability (2) the capacity of subcutaneous bapineuzumab to reduce brain amyloid load as measured by positron emission tomography (PET) scans.
What is the current status of trial NCT01254773?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2010-12. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01254773?
The interventions under investigation include: Experimental Bapineuzumab (DRUG).
Who is sponsoring clinical trial NCT01254773?
This trial is sponsored by JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.